Patient Follow-up

Radiomics is actively working on providing automated image-based endpoints to follow up the evolution of solid tumors in cancer patients. In this framework, we are about to launch our SALMON trial to validate an automatic calculation of the current RECIST scoring (aRECIST, mainly looking at tumor size) and to initiate the work on a next generation optimized RECIST scoring (oRECIST, considering the full tumor phenotype).